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Arthroplasty is a surgical procedure with expanding indications and 
increasing use worldwide [1-3]. Serious complications following 
primary total hip or knee replacement are generally fewer than 5% [4]. 
Among them, prosthetic joint infections (PJIs) are the third cause of 
prosthesis revision and are associated with both prolonged 
hospitalization and increased costs [5-7].  
Management of PJIs includes both surgical and medical interventions 
and ranges from conservative (medical therapy only) to radical 
(amputation) strategies [8]. Debridement, antibiotics and implant 
retention (DAIR) is a semi-conservative approach primarily indicated 
for early post-operative and acute hematogenous infections of a well-
fixed prosthesis with no sinus tract and a susceptible pathogen [9]. 
However, it can be considered also for patients who do not meet these 
criteria but cannot or refuse to undergo alternative surgical strategies 
[8]. Compared to two-stage reimplantation, reported advantages of 
DAIR are avoiding invasive surgery and allowing patient’s short-term 
functional recovery [10]. However, success rates widely vary in 
literature, ranging from 16% to 75% [11], and numerous risk factors for 
DAIR failure have been investigated with conflicting results across 
studies [10]. Moreover, uncertainties exist about the optimal duration 
of antibiotic treatment after debridement and implant retention: while 
current guidelines recommend long courses of antibiotics (e. g. 12-24 
weeks for staphylococcal PJIs) [8], shorter treatment regimens (8 
weeks) have been recently explored with encouraging results [12].  
The primary aim of this study is to report the outcome of DAIR in a 
series of patients with hip and knee PJIs. The secondary aim is to 
identify risk factors for DAIR failure.   
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MATERIAL AND METHODS 
Setting and study design 
Quadrante Orthopedic Center (Centro Ortopedico di Quadrante, COQ) 
is an orthopedic hospital located in Omegna, northern Italy, highly 
specialized in prosthetic surgery (850 implants/year). Patients refer to 
this center for both primary arthroplasty and reintervention in case of 
aseptic/septic complications. The center adheres to the National 
Surveillance program for Surgical Site Infections [13] according to 
which, one year after arthroplasty patients are asked to complete a 
questionnaire to assess if they had developed a surgical site infection. 
Since 2013, an integrated approach involving orthopedic surgeons, 
infectious disease physicians and infection control nurses is 
systematically applied at the center. This multidisciplinary approach is 
adopted for the drafting of infection-control protocols, selection of 
candidates for arthroplasty and definition of the diagnostic-therapeutic 
pathways of patients with a suspected PJI.  
We performed a retrospective study on prospectively collected data of 
all hip and knee PJIs consecutively diagnosed at COQ from 1st January 
2013 to 1st January 2019 and we selected those treated with DAIR. The 
follow-up was stopped on 31st January 2020. We excluded patients 
referred from other centers, for whom a proper follow-up could not be 
guaranteed. All procedures were performed in accordance with the 
ethical standards of the institutional and/or national research committee 
and with the 1964 Helsinki Declaration and its later amendments or 
comparable ethical standards. Upon enrolment, all patients signed a 





Procedures and definitions 
For each patient with a PJI treated with DAIR, the following information 
was collected: demographic data, body mass index (BMI), Charlson 
age-comorbidity index [14], involved joint (hip or knee), previous joint 
procedures (primary arthroplasty or revision), time from implant to 
diagnosis of infection, isolated pathogen, time from diagnosis of 
infection to surgical intervention, antimicrobial therapy and outcome. 
PJI was defined according to the 2011 definition of the Workgroup of 
the Musculoskeletal Infection Society [15]. PJI was classified as early 
(within one month from the implant), delayed (between two and six 
months) and late (after six months) [16]. Success was defined according 
to the Delphi-based international multidisciplinary consensus: (i) 
infection eradication, (ii) no needing for further surgical interventions 
for infection and (iii) no PJI-related mortality recorded after at least 12 
months of follow-up [17]. Failure was defined as (i) 
persistence/recurrence of signs of infection after the end of antibiotic 
treatment, (ii) needing for further surgical interventions and (iii) PJI-
related death. 
 
Clinical and surgical management 
At COQ, all patients with a PJI are hospitalized in the unit dedicated to 
musculoskeletal infections. Presence of sinus tract, unstable implant 
and pre-operative isolation of multi drug-resistant pathogen are 
considered major contraindications to DAIR [18]. Per center protocol, 
antibiotics are not administered before surgery, unless in case of 
systemic infection. In case of DAIR prescription, surgical procedure is 
performed via open arthrotomy and consists in extensive debridement 
of necrotic and infected tissues, profound joint irrigation with sterile 
saline, assessment of the prosthesis stability and replacement of the 
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prosthesis mobile components (polyethylene in case of knee 
involvement and polyethylene plus femoral head in case of hip) [12]. 
During surgery, three to five samples of periprosthetic tissue and one 
sample of synovial fluid are collected for microbiological culture. Then, 
an empiric, broad-spectrum intravenous antibiotic therapy is started. 
Standard regimen includes vancomycin (30 mg/kg/day) or teicoplanin 
(8-10 mg/kg for the first three doses followed by 8-10 mg/kg/day) plus 
ceftriaxone (2 g/day). When the infective organism and his 
susceptibility test results are available, targeted therapy is provided. 
After about two weeks of intravenous treatment, switch to oral therapy 
is done. Cornerstone oral antibiotics include fluoroquinolones and 
tetracycline; rifampin is added in case of staphylococcal infection if no 
contraindications are present. After hospital discharge, monthly follow-
up visits are performed. At the same timepoints C-reactive protein 
(CRP) concentrations are measured. Antibiotic treatment is prescribed 
for approximately, respectively, 8 and 12 weeks from hip and knee 
surgery. Case-by-case antibiotic duration is established according to 
clinical judgement and CRP level normalization (<0.5 mg/dl). After 
completion of the antibiotic treatment, follow-up is performed every 
four months for the first year. For the present study, a telephone 
interview was held with all patients by 31 January 2020 to investigate 
whether they had experienced PJI relapse.  
 
Statistical analyses 
The incidence of PJIs was calculated at 30 days and one year after 
arthroplasty as ratio between cases of infections and survived patients 
that completed the surveillance questionnaire at one year of follow-up. 
A descriptive analysis evaluated the main patients’ characteristics. The 
continuous variables (age, duration of antibiotic treatment and follow-
7 
 
up) were expressed as the means and range or the medians and 
interquartile ranges (IQRs). The categorical variables were sex, BMI, 
Charlson age-comorbidity index, prosthesis type, arthroplasty history, 
time of symptoms onset, isolated pathogens and antibiotic treatment. 
Chi-square tests or Fisher's exact test were used to compare categorical 
variables, while Mann-Whitney test was used for continuous variables. 
Multivariate logistic regression analysis was conducted including 
variables with p<0.15 in univariate analysis. P values <0.05 were 
considered statistically significant. SPSS v.22.0 (SPSS Inc., Chicago, 





During the study period, 5102 hip and knee arthroplasty procedures 
(hip=2702, 53%; knee=2400, 47%) were performed at our center. All 
patients but one, who died for myocardial infarction five days after hip 
implantation, were alive and underwent a visit at 30 days follow-up. Of 
them, forty-seven developed a PJI (hip=24, 51%; knee=23, 49%), with 
an infection rate of 0.9% (24/2701) for hip, 1% (23/2400) for knee. 
Three patients deceased within one year follow-up for causes not 
related to surgical intervention. Out of 5098 survived patients, 3923 
(77%) responded to the surveillance questionnaire one year after 
arthroplasty. Incidence of PJIs in these patients actively followed at one 
year follow-up was 1.2%.  
Twenty-one patients (45%) among 47 with PJI were treated with DAIR 
for hip (13/21, 62%) and knee (8/21, 38%) PJIs and were included in 
subsequent analyses. They had mean age of 71 years (range 50-86), 
62% (n=13) were female, 57% (n=12) were obese (BMI30) and 48% 
(n=10) had a Charlson age-comorbidity index >3. The most common 
comorbidity was hypertension (n=11, 52.4%), followed by diabetes 
(n=3, 14.3%) and history of cancer (n=3, 14.3%). 
In all cases osteoarthritis was the reason for primary arthroplasty. Four 
patients had already experienced a surgical revision of the primary 
implant because of prosthesis dislocation/instability. PJI was classified 
as early in 76% (16/21) cases, delayed in 19% (4/21) and late in 5% 
(1/21). Reasons for choosing DAIR in five patients with a late/delayed 
PJI were: acute hematogenous infection (treated within 8 and 10 days 
from presentation, two cases); surgical indication (rescue attempt of a 
cemented prosthesis whose explant would have been particularly 
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destructive, two cases); patient’s refusal to undergo major surgery (one 
case).  
An etiologic agent was identified in 86% (n=18) of patients: 
staphylococci were the most common pathogens (n=12, 66.6%), 
followed enterococci (n=3, 16.6%). Microbiological details are shown 
in Table 1. 
 
Table 1. Pathogens isolated in 18 patients with prosthetic joint infection 
Pathogen N  % 
Gram-positive cocci 



























Median time from PJI-related symptoms onset to implant revision 
surgery was 12 days (IQR, 7 to 20 days); in 81% (17/21) of cases 
surgery was performed within 21 days from symptoms onset.  
In accordance with local protocol, empiric therapy included a 
glycopeptide (vancomycin or teicoplanin) plus ceftriaxone in all 
patients: this combination regimen resulted effective against all the 
isolated pathogens according to their antibiotic resistance profiles. As 
for step down therapy (targeted in 18 cases, empiric in 3), 
fluoroquinolones were the most commonly prescribed antibiotics (10 
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patients, 48%), followed by tetracyclines (7, 33%), amoxicillin +/- 
clavulanate (3, 14%) and teicoplanin (1, 5%). Rifampin-based 
combination therapy was prescribed for 9 (43%) patients (in association 
with fluoroquinolones in 4 cases, tetracyclines in 4, amoxicillin in 1); 
non-rifampin based combination therapy (levofloxacin plus 
minocycline) was prescribed to 1 patient. The median duration of 
antibiotic treatment after surgery was 63 days (IQR, 53 to 84 days). No 
clinically significant drug-related adverse events were reported and all 
patients were able to complete the prescribed antibiotic course. The 
median duration of follow-up was 1001 days (IQR, 463 to 2321 days). 
Sixteen (76%) patients were cured after a median follow-up of 2197 
days (IQR, 815 to 2342 days), while 5 (24%) patients experienced 
failure after a median of 133 days (IQR, 101 to 463 days) from surgery. 
Four of them underwent two-stage exchange surgery while one 
underwent knee arthrodesis, obtaining clinical remission. Features and 
outcome of the patients included in the study are summarized in Table 
2.  
 
Table 2. Features and outcome of 21 patients treated with debridement, antibiotics and 




























































































































































































































DAIR debridement, antibiotics and implant retention *Hematogenous infection 
 
Analyses of factors associated with failure are shown in Table 3.  
At univariate analysis, having a knee PJI and a delayed/late PJI were 
factors significantly associated with failure (OR=12.0; 95% CI 1.02-
141.37, p=0.05 and OR=60.0; 95% CI 3.04-1185.04, p=0.004, 
respectively). Having an age equal or over the median and having a 
Charlson age-comorbidity index >3 showed a trend to worse outcome, 
but these variables were not significant (OR=1,93; 95% CI 0.25-14.89 
and OR=1.94; 95% CI 0.25-14.89). Besides, performing surgery within 
21 days from symptoms onset and using fluoroquinolones showed a 
trend to better outcome, but they did not reach statistical significance 
(OR=4.67; 95% CI 0.46-47.63 and OR=0.19; 95% CI 0.02-2.15). We 
find no statistical association between treatment failure and patients’ 
sex and BMI, revised implant, isolated pathogens, rifampicin co-
administration or antibiotic treatment duration (Table 3). Multivariate 
analysis confirmed that a delayed/late PJI was significantly associated 
with failure (OR=12.51; 95% CI 1.21-129.63, p=0.03) (Table 2).  
 




Univariate analysis Multivariate analysis 
Failure 
(n = 5) 
Success 
(n = 16) 
p  
value 
OR               





Median age (range) 75.6 (67-86) 70.1 (50-82) 0.63   
Female 3 (60%) 10 (62.5%) 0.92   
Overweight/obese* 3 (60%) 14 (87.5%) 0.17   
Charlson age-comorbidity 
index >3 
3 (60%) 7 (43.8%) 0.53   
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Type of prosthesis     0.05  0.34 
   Hip 1 (20%) 12 (75%) 
 
1.00  





History of arthroplasty 
  
0.70   
   Primary implant 4 (80%) 13 (81.2%) 
 
  





0.004  0.03 
   Early 1 (20%) 15 (93.8%) 
 
1.00  





Time between symptoms 
onset and DAIR (days) 
     0.17   
   > 21 2 (40%) 2 (12.5%)     
   < 21 3 (60%) 14 (87.5%) 
 
  
Isolated pathogens (n=18) 
   
  
   S. aureus 2 (40%) 6 (37.5%) 0.92   
   Other gram-positive 
cocci** 
2 (40%) 6 (37.5%) 0.92   
   Gram-negative bacilli*** 0 (0%) 2 (12.5%) 0.41   
Cornerstone antibiotic 
class 
        
   Fluoroquinolones 1 (20%) 9 (56.2%) 0.31   
   Tetracycline 2 (40%) 5 (31.2%) 1.00   
   Penicillins 2 (40%) 1 (6.3%) 0.13   
   Glycopeptides 0 (0%) 1 (6.3%) 0.76   
Rifampicin-based 
combination therapy 
3 (60%) 6 (37.5%) 0.38   
Median (range) duration of 
antibiotic treatment (days) 
        
   Hip 63 (63-63) 64.2 (28-91) 1.00   
   Knee 78 (42-144) 106.8 (49-154) 0.24   
Median (IQR) duration of 
antibiotic treatment (days) 
63 (52.5-103.5) 63 (50.8-84) 0.77   
Duration of antibiotic 
treatment 
  0.48   
   ≥12 weeks 1 (20%) 6 (37%)    
   <12 weeks 4 (80%) 10 (63%)    
* BMI 25 
**Coagulase-negative staphylococci (n=4), E. faecalis (n=3), S. mitis (n=1) 




In this study, we found a 76% success rate of DAIR in patients receiving 
early surgical debridement and short course of antibiotic treatment. 
Additionally, delayed/late infection was the only risk factor for DAIR 
failure we observed.  
The incidence of infections of hip and knee prosthesis implanted at 
COQ during the study period we reported is consistent with the 
literature data, which report an infection rate of 0.76-1.24 percent for 
hip arthroplasty and 0.88-1.28 percent for knee arthroplasty [19]. This 
result reflects the high level of expertise of our center and the systematic 
application of an integrated approach among orthopedic surgeons, 
infectious diseases specialists and infectious risk nurses during all 
phases of arthroplasty (selection of the patient, prescription of antibiotic 
prophylaxis, surveillance of surgical site infections etc.). 
DAIR is an attractive treatment option for PJIs. However, its efficacy 
is debated as, according to the patient selection criteria and surgical 
techniques used across studies, efficacy rates could be as low as 16% 
[11]. In the present study, we found DAIR to have a high success rate 
(76%) which is consistent with that observed by other authors (from 
66% to 86%) in cohorts of comparable elderly and comorbid patients. 
[20-25]. Notably, we obtained similar success rate in spite of shorter 
duration of antibiotic treatment after DAIR procedure. Indeed, our 
median treatment duration was 63 days with 71% of patients receiving 
antibiotics for less than three months, while Byren et al. administered 
antibiotics for a minimum of 12 months in every patient, 
Grammatopoulos et al. for at least 6 months and Peel et al. for a median 
of 341 days [21, 24-25]. 
2013 guidelines by the Infectious Diseases Society of America 
recommend a long course of antibiotics after debridement and implant 
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retention (e.g. 3 and 6 months for hip and knee staphylococcal 
infections, respectively) and some authors advocate the use of indefinite 
suppressive therapy for selected patients [8, 18]. However, these 
recommendations raise concerns about the possible occurrence of side 
effects and antibiotic resistance selection. Here, we confirmed that short 
treatment course did not negatively impact on infection eradication. 
Moreover, we observed that all patients completed the prescribed 
treatment without experiencing any relevant side effects, while studies 
with longer antibiotic treatment reported a high incidence of adverse 
events (up to 28%) [26-27]. Unfortunately, due to the observational 
design of our study we were not able to demonstrate that shorter 
treatment is as effective as longer treatment, but very high rate of 
success in case of early PJIs (94%) suggest that this approach might be 
feasible. However, the possibility of an indication bias cannot be 
excluded, given that short-term therapy may have been prescribed only 
to patients with a favorable course and fewer risk factors for failure. In 
recent years several authors explored the efficacy of short courses of 
antibiotics in patients treated with DAIR and observed encouraging 
results [23, 28-33]. In particular, Lora-Tamayo et al. in a prospective 
randomized clinical trial on staphylococcal PJIs managed with DAIR 
found similar cure rates in patients treated with eight weeks of 
antibiotics compared with patients managed with standard (3 or 6 
months for hip or knee prosthesis) schedule (91.7 and 95%, 
respectively) [33]. Further randomized trials are warranted to confirm 
this finding.  
Importantly, we found that all but one of early postoperative PJIs were 
cured after DAIR while delayed/late PJIs were strongly associated with 
treatment failure. This result is widely confirmed in literature [21, 34-
35] and is coherent with the general recommendation of considering 
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DAIR for the treatment of early postoperative PJIs [18]. The rationale 
is that in early postoperative infections the bacterial colonization is still 
limited, the biofilm is not fully structured (although already present) 
and the infection is confined to the joint space: in this phase, therefore, 
aggressive irrigation and debridement of the infected tissues followed 
by mobile parts exchange and by the administration of antibiotics can 
led to infection eradication [9]. On the contrary, delayed/late infections 
are characterized by a mature biofilm, which protects bacteria from both 
immune system and antibiotics, and by a greater extension of the 
infectious process: these factors strongly reduce the likelihood that a 
semi-conservative approach such as DAIR will allow the eradication of 
the infection However, there are patients for whom less conservative 
surgical strategies (e.g. two-stage revision) are unacceptable or too 
risky, so that DAIR can be considered even in presence of 
contraindications, such as delayed/late infections. Our experience 
confirms that the probability of success in this context is reduced, so it 
is necessary to consider this option only in extreme cases and to 
extensively discuss this choice with patients. 
Previous studies identified other risk factors for DAIR failure, such as 
causative microorganisms (S. aureus and Gram-negative bacilli in 
particular) [36-37], knee involvement (compared to hip, elbow and 
shoulder) [38] and previously revised joints [21], while others did not 
[39-41]. Our results do not confirm the role of factors other than 
prosthesis age in predicting DAIR failure, possibly because of the 
limited sample size and, furthermore, we did not find the favorable 
impact of rifampin-based combination therapy advocated by some 
authors [42-43]. Since several variables have been proposed as 
predictors of DAIR failure, randomized prospective studies are 
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warranted to validate these risk factors and to use them in the selection 
of candidates to DAIR. 
In our study, empiric therapy directed against staphylococci (included 
oxacillin-resistant strains) and gram-negative bacilli was effective in all 
patients. As for targeted therapy, the antibiotic class did not 
significantly influence remission rates, but the limitation of small 
sample size should be acknowledged. According to 2013 IDSA 
guidelines and per center protocol, cornerstone oral antibiotics included 
fluoroquinolones and, as second-line treatment, tetracycline, together 
with rifampin in case of S. aureus. Fluoroquinolones were the most 
commonly prescribed step-down drugs, thanks to their peculiar 
features: excellent bone penetration, intra-cellular accumulation, high 
oral bioavailability and strong bactericidal activity against S. aureus 
and gram-negative bacilli [44-45]. However, fluoroquinolones 
resistance is increasing worldwide making narrow spectrum antibiotics 
a more fashionable option. Some of them, including oxacillin and 
cefazolin, have shown good penetration into bone and joint tissues 
reaching concentrations exceeding the MIC90 and/or MIC breakpoints 
of common bone and joint infections pathogens. Further studies are 
needed to evaluate the best antibiotic treatment strategy in patients 
receiving DAIR.  
Notably, we obtained a high rate of microbiological diagnosis (86%) in 
patients with PJI. Prevalence of culture-negative PJIs varies across 
studies, ranging from 0% to 42% [46]. Several factors can interfere with 
microbiological yield: prior administration of antibiotic therapy, 
insufficient material sent for culture, fastidious organisms and biofilm 
action [47]. In our series, the three patients who had a culture-negative 
PJI had not received any antibiotics before starting their diagnostic 
work-up. They were empirically treated with tetracycline plus rifampin 
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(2 cases) and ciprofloxacin (1 case) and only one experienced failure. 
Although there is no consensus on the optimal antibiotic therapy for 
culture-negative PJIs [46-47], our choice aimed to cover the most 
common causative pathogens of PJIs, id est S. aureus and coagulase-
negative staphylococci who are responsible for the 50-60% of PJIs [9].  
Main limitations of this study are the single-center retrospective design 
and small sample size. On the other hand, all patients were managed 






Our study confirms that DAIR represents an effective strategy for the 
treatment of early PJIs when performed in a specialized center that 
rigorously apply an integrated approach between surgeons, infectious 
diseases physicians and infection control nurses. Larger prospective 
studies are needed to assess the optimal antibiotic duration after 
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